Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Edelstein

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Biorxiv : the Preprint Server for Biology|February 9, 2026
Epithelial Reprogramming and Transition during Pulmonary BioengineeringSatoshi Mizoguchi, Vi Lee, Hahram Kim, et al.
JCI Insight|September 9, 2025
Virologic characteristics of SARS-CoV-2 infection across evolving Omicron subvariantsJulie Boucau, Owen T Glover, Caitlin Marino, et al.
Annals of Internal Medicine|November 13, 2023
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational StudyGregory E Edelstein, Julie Boucau, Rockib Uddin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 10, 2023
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapyGregory E Edelstein, Julie Boucau, Rockib Uddin, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
COVID-19 induces persistent transcriptional changes in adipose tissue that are not associated with Long COVIDSoneida DeLine-Caballero, Kalani Ratnasiri, Heping Chen, et al.
Microbiology Spectrum|May 18, 2026
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolutionGregory E Edelstein, Tatum N Sass, Rinki Deo, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2026
Post-infection immune response in adults with COVID-19 with and without nirmatrelvir-ritonavir treatment and virologic reboundDibya Ghimire, Chloe M Hasund, John Bianchi Colangeli, et al.
Journal of Virology|February 4, 2025
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 16, 2025
Protracted SARS-CoV-2 Infection in B-cell Depleted Patients: Immunologic andiral Characteristics and Response to Dual and Extended Antiviral TherapyJessica S Little, Gregory E Edelstein, Zoe Swank, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Biorxiv : the Preprint Server for Biology|February 9, 2026
Epithelial Reprogramming and Transition during Pulmonary BioengineeringSatoshi Mizoguchi, Vi Lee, Hahram Kim, et al.
JCI Insight|September 9, 2025
Virologic characteristics of SARS-CoV-2 infection across evolving Omicron subvariantsJulie Boucau, Owen T Glover, Caitlin Marino, et al.
Annals of Internal Medicine|November 13, 2023
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational StudyGregory E Edelstein, Julie Boucau, Rockib Uddin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 10, 2023
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapyGregory E Edelstein, Julie Boucau, Rockib Uddin, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
COVID-19 induces persistent transcriptional changes in adipose tissue that are not associated with Long COVIDSoneida DeLine-Caballero, Kalani Ratnasiri, Heping Chen, et al.
Microbiology Spectrum|May 18, 2026
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolutionGregory E Edelstein, Tatum N Sass, Rinki Deo, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2026
Post-infection immune response in adults with COVID-19 with and without nirmatrelvir-ritonavir treatment and virologic reboundDibya Ghimire, Chloe M Hasund, John Bianchi Colangeli, et al.
Journal of Virology|February 4, 2025
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 16, 2025
Protracted SARS-CoV-2 Infection in B-cell Depleted Patients: Immunologic andiral Characteristics and Response to Dual and Extended Antiviral TherapyJessica S Little, Gregory E Edelstein, Zoe Swank, et al.
Pageof 9